Musan Yan

Musan Yan

Auto-generated profile, based on publicly available information

Musan Yan

School of Basic Medicine, Qingdao University, Qingdao, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Blood
Verified
Journal Article
Open access
MXMin Xue
Min Xue
SWShaoying Wang
Shaoying Wang
CLChangjiang Li
Changjiang Li
YWYuewei Wang
Yuewei Wang
MLMing Liu
Ming Liu
XTXiaopeng Tang
Xiaopeng Tang
Coagulation is related to inflammation, but the key pathway, especially innate immune system and coagulation regulation, is not well understood and need to be further explored. Here, we demonstrated that neutrophil gelatinase-associated lipocalin (NGAL), an innate immune inflammatory mediator, is upregulated in patients with thrombosis. Furthermore, it contributes to the initiation and amplification of coagulation, hemostasis, and thrombosis. This occurs by enhancing tissue factor expression on the cell surface, potentiating various clotting factors such as thrombin, kallikrein, factor XIa (FXIa), and FVIIa, promoting thrombin-induced platelet aggregation, and inhibiting antithrombin. NGAL knockout led to strikingly prolonged clot reaction time and kinetic time in thromboelastography analysis, along with reduced thrombus generation angle and lower thrombus maximum amplitude, which were in line with remarkably prolonged activated partial thromboplastin time and prothrombin time. In several mouse hemostasis and thrombosis models, NGAL overexpression or IV administration promoted coagulation and hemostasis and aggravated thrombosis, whereas NGAL knockout or treatment with anti-NGAL monoclonal antibody significantly prolonged bleeding time and alleviated thrombus formation. Notably, NGAL knockout prolonged mouse tail bleeding time or artery occlusion time to over 40 or 60 minutes, respectively, resembling uncontrollable bleeding and clotting disorder seen in hemophilic mice. Furthermore, anti-NGAL monoclonal antibody treatment markedly reduced the formation of blood clots in inflammation-induced thrombosis models. Collectively, these findings unveil a previously unidentified role of NGAL in the processes of coagulation, hemostasis, and thrombosis, as well as the cross talk between innate immunity, inflammation, and coagulation. Thus, modulating NGAL levels could potentially help balance thrombotic and hemorrhagic risks.

4 May 2026 in Blood
Verified
Journal Article
Closed access
SLShiping Lin
Shiping Lin
YYYuanjie Yin
Yuanjie Yin
SWShaoying Wang
Shaoying Wang
CLChuanfeng Liu
Chuanfeng Liu
MYMusan Yan
Musan Yan
XTXiaopeng Tang
Xiaopeng Tang
Inflammation and coagulation are intricately linked. Although some studies have documented pro-inflammatory drivers of coagulation, the role of anti-inflammatory cytokines and the underlying mechanisms in the modulation of coagulation, platelet function, and thrombosis remain poorly characterized. In this study, we demonstrated that interleukin-4 (IL-4), an anti-inflammatory cytokine, plays a crucial role in regulating platelet function and thrombus formation. IL-4 inhibited collagen-induced intracellular calcium mobilization, P-selectin expression, ATP release, integrin αIIbβ3 activation, platelet spreading, and platelet aggregation. IL-4 binds to residues 38-46 within GPVI's extracellular collagen-binding domain and suppresses downstream signaling by inhibiting phosphorylation of phospholipase Cγ2 and protein kinase C. A GPVI-derived interfering peptide (RR9) binding to IL-4 disrupted the IL-4-GPVI complex and reversed the inhibitory effects of IL-4 on platelets. In vivo, IL-4 overexpression or intravenous administration inhibited platelet intracellular calcium mobilization, ATP release, and aggregation, prolonged bleeding time, and attenuated both arterial and venous thrombosis. Conversely, IL-4 knockout, anti-IL-4 antibody treatment, or RR9 treatment enhanced platelet reactivity, promoted hemostasis, and aggravated thrombosis. Our findings reveal that IL-4 negatively regulates platelet function through direct interaction with GPVI, thereby facilitating crosstalk among inflammation, hemostasis, and thrombosis. Therefore, modulating IL-4 levels provides a novel strategy for treatment of thrombotic disorders.

14 September 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWShaoying Wang
Shaoying Wang
MXMin Xue
Min Xue
MYMusan Yan
Musan Yan
CLChuanfeng Liu
Chuanfeng Liu
MWMengmeng Wang
Mengmeng Wang
XTXiaopeng Tang
Xiaopeng Tang
Hypertension has paradoxical prothrombotic-hemorrhagic predisposition toward cerebral infarction and intracerebral hemorrhage (ICH), but the mechanism remains poorly understood. We observed Angiotensin II (Ang II) inhibited coagulation by activating antithrombin through heparin-like acceleration of antithrombin-thrombin interaction. Ang II allosterically modulates the 386-397 loop of antithrombin to enhance thrombin inhibition. In vivo, single injection of Ang II inhibited coagulation, alleviating thrombosis and aggravating ICH. Conversely, anti-Ang II monoclonal antibody promoted coagulation, aggravating thrombus formation and alleviating ICH. Notably, the blockage or deficiency of Ang II receptor had no significant effect on the alleviated thrombus formation or aggravated hemorrhage elicited by Ang II, suggesting the phenotypes were independent of Ang II receptor. In hypertensive mice, anti-Ang II monoclonal antibody significantly promoted coagulation and ameliorated ICH. These results identify Ang II as a key coagulation regulator with heparin-like function, suggesting that targeting Ang II-coagulation pathway could be a novel strategy to mitigate cerebral bleeding.